



Formulary 2 Updates February 12, 2026

The following drug products were reviewed and acted upon by the CDPHP Pharmacy and Therapeutics Committee for Formulary 2.

ACA Covered under the Affordable Healthcare Act-no member cost share

PA Prior authorization required

PD Preventive Drug

QL Quantity Limits Apply

SP Restricted to ConnectRx or CVS Caremark Specialty Pharmacy

ST Step Therapy

DUR Subject to Drug Utilization Review

Drug	Previous Coverage	Coverage
Cladribine Tablet Pack	New generic	Tier 3, PA
Redemplo (plozasiran) Subcutaneous	New to Market	Tier 3, PA, QL
Hyrnuo (sevabertinib) Tablets	New to Market	Tier 3, PA, QL
Voyxact (sibeprenlimab) Subcutaneous	New to Market	Tier 3, PA, QL
Komzifti (ziftomenib) Capsules	New to Market	Tier 3, PA, QL
Apretude (cabotegravir) Injection	Non-Formulary	Tier 3, QL
Yeztugo (lenacapavir) Injection	Non-Formulary	Tier 3, QL
Divigel (estradiol) Gel	Non-Formulary	Tier 3, QL
FreeStyle Libre Devices	Tier 2, QL, DUR	Tier 2, QL
Dexcom Devices	Tier 2, QL, DUR	Tier 2, QL